Abstract 1327
Background
Oxaliplatin is frequently used in the treatment of gastrointestinal cancer patients. A known side effect of oxaliplatin administration via a peripheral vein is infusion-related pain. In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 ml glucose 5% in 2 hours).
Methods
As of December 2017, all patients treated with oxaliplatin at the Jeroen Bosch Hospital in the Netherlands received simultaneous FI. We retrospectively defined two cohorts: Patients treated with oxaliplatin and simultaneous intravenous FI starting treatment between January and November 2018, and the same number of patients treated without FI between January and November 2017. The incidence of infusion-related venous pain was the primary outcome measure. Secondary outcomes included: Incidence of hypersensitivity reactions, infusion time, dose density, the number of patients switched to a central venous catheter and the incidence of peripheral neuropathy. Chi-square tests for categorical variables and T- tests for continuous variables were used. To identify possible confounders, we conducted a multivariate logistic regression analysis.
Results
100 patients were included: 50 patients in the FI group, 50 patients in the group treated without FI. Baseline characteristics were comparable, except for age (median 66.8 versus 62.4 years in groups with and without FI; p = 0.017), and BMI (28.0 versus 25.7 kg/m2 respectively; p = 0.012). Patients treated with simultaneous FI experienced significantly less vascular pain compared to those without FI (10% versus 78% respectively (p < 0.0001; OR 0.031 (95% CI: 0.01-0.098)). No difference was observed in dose density, treatment delay, or the need of central venous catheter. Multi-variate regression analysis showed no confounders affecting the primary outcome. No adverse events of FI were observed.
Conclusions
Concurrent infusion of 800ml glucose 5% with peripheral venous administration of oxaliplatin significantly reduces the incidence of infusion-related pain in gastrointestinal cancer patients and is highly feasible and affordable in every-day clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract